Search

MLN2222

MLN2222 is a novel, proprietary recombinant protein that blocks both the C3 and C5 convertases, which are essential components of the complement activation pathway.

Interferon alfa

Interferon alfa contains several naturally occurring IFN-α subtypes and is purified by affinity chromatography.

Neisseria meningitidis group A capsular polysaccharide tetanus toxoid conjugate antigen

Neisseria meningitidis group C capsular polysaccharide tetanus toxoid conjugate antigen

Amsacrine

It produces consistent but acceptable myelosuppression and cardiotoxic effects. … It is effective in the treatment of acute leukemias and malignant lymphomas, but has poor activity in the treatment of solid tumors.

Quercus alba pollen

Quercus alba pollen, or oak white pollen, is a non-standardized allergen extract used for the diagnosis and treatment of allergic disease to grass pollen. It can be subcutaneously administered to initiate an immune response in case of an...

Chromium

Chromium chloride is available as an intravenous injection for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN) [FDA Label].

Hyoscyamine

Hyoscyamine is a tropane alkaloid and the levo-isomer of atropine. It is commonly extracted from plants in the Solanaceae or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyami...

Fondaparinux

Once bound to heparin or HS, the anticoagulant activity of ATIII is potentiated by 1000-fold. Fondaparinux potentiates the neutralizing action of ATIII on activated Factor X 300-fold. … undergoing abdominal surgery who are are at high risk of thromboembolic complications; in the treatment of deep vein thrombosis (DVT) and pumonary embolism (PE); in the management of unstable angina (UA

Nialamide

Withdrawn from the Canadian, US, and UK markets in 1963 due to interactions with food products containing tyrosine.